Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | CPN1 | P15169 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6366263 | 1.00 | HDAC4 (0.49) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL6366254 | 1.00 | HDAC4 (0.49) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL2864430 | 0.84 | ROCK2 (0.49) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL27953660 | 0.84 | MEN1 (0.48) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL29421137 | 0.84 | AKR1C3 (0.51) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL2016833 | 0.84 | AKR1C3 (0.51) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL30371733 | 0.84 | CNR2 (0.50) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL25242939 | 0.80 | HDAC4 (0.47) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL31038318 | 0.80 | HDAC4 (0.47) | HDAC4HDAC7HDAC5CNR2CES2 | |
| SCHEMBL4022595 | 0.80 | CYP2C19 (0.68) | HDAC4HDAC7HDAC5CNR2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838478-B2 | Amino acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | disclosed |
| EP-0910573-B1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| US-20020019371-A1 | New amino acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-14 | — | — | US | disclosed |
| US-6255301-B1 | CARDIOVASCULAR DISORDERS; ANTICOAGULANT; PROTEASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-07-03 | — | — | US | disclosed |
| EP-0910573-A1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997046577-A1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019371-A1 | New amino acid derivatives and their use as thrombin inhibitors | F2, SERPINC1, FGB | HDAC4 4373/4885HDAC7 4007/4885HDAC5 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.